Lenva
Lenvatinib is FDA approved for the treatment of radioactive iodine-refractory differentiated thyroid cancer (DTC), unresectable or advanced hepatocellular carcinoma (HCC), and advanced renal cell carcinoma (RCC). It is a multiple receptor tyrosine kinase inhibitor that demonstrates potent antiangiogenic properties.
Features
| Product Name | Lenva |
| Generic Name | Lenvatinib Mesylate |
| Therapeutic Class | TKI |
| Formulation | Solid |
| Available Pack Size | 2x8's, 2x6's |
| Available Strength | 4 mg, 10 mg |